Contact Us
TEL: +86-0571-88334626
E-mail: sales@tacon-china.com.cn
Home > News > Content
Research And Development Of Biopharmaceuticals
Jun 02, 2018

Biopharmaceutical is a method of producing drugs using living organisms. For example, transgenic maize was used to produce human antibody, transgenic bovine breast tissue expressed human trypsin 1. Biopharmaceutical industry prospects, the biosynthesis of pharmaceuticals for half the world is, it will be widely used in the treatment of cancer, AIDS, coronary heart disease, anemia, dysplasia, a variety of diseases such as diabetes. Most of the antibiotics used in medicine come from microorganism, such as erythromycin, jiemycin, penicillin, streptomycin, gentamycin and so on. The number of people engaged in the research, development, production and operation of the biotechnology industry in China is only one quarter of that in the United States. Talents engaged in the research and development of biomedical products are seriously insufficient, which has become the bottleneck restricting the development of China's biomedical industry.

The development of domestic biopharmaceutical industry is characterized by small scale, low concentration and fast growth.

From 2006 to 2010, China's biopharmaceutical industry grew by 272%. Although the sales of China's biopharmaceutical industry has increased significantly, it is only close to the sales of amgen, an American biochemical company. The annual sales volume of the five listed companies of hualan biology, tiantan biology, kehua biology, shuanglu pharmaceutical and da 'an gene only accounts for about 4% of the market share. The production capacity structure of China's biopharmaceutical enterprises is unbalanced, the production capacity of high-end drugs is insufficient, and the production capacity of low-end drugs is excessive. Such as vaccine production in China more than half of the product is used to prevent polio, common diseases such as measles vaccine, corrosive cutting-edge cancer, AIDS vaccine development, at present I in biopharmaceutical industry enterprise product independent research and development ability are relatively weak, give priority to with generics and active pharmaceutical ingredients, competition ability is poor. China has approved the listing of only about 5 percent of the original biopharmaceuticals, the vast majority for generic drugs. Only a small number of domestic biopharmaceutical companies are close to the international level in r&d investment in the domestic biopharmaceutical industry.